Citation Impact
Citing Papers
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
2003 Standout
Characterization of Functional Excision Repair Cross-Complementation Group 1 Variants and Their Association with Lung Cancer Risk and Prognosis
2008
Comprehensive computational design of ordered peptide macrocycles
2017 StandoutScienceNobel
In Vitro and In Vivo Gene Therapy Vector Evolution via Multispecies Interbreeding and Retargeting of Adeno-Associated Viruses
2008
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy in Advanced Non–Small-Cell Lung Cancer
2007
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Standout
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
2010 Standout
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
2003 Standout
A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer
2014
First-line chemotherapy for NSCLC: an overview of relevant trials
2002
EGFR Antagonists in Cancer Treatment
2008 Standout
Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: A phase II trial
2001
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Chemotherapy for small cell lung cancer
2003
Improving Survival and Reducing Toxicity with Chemotherapy in Advanced Non-Small Cell Lung Cancer
2005
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
The Role of the p53 Tumor Suppressor Gene in Squamous Cell Carcinoma of the Head and Neck
1993
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Development of next generation adeno-associated viral vectors capable of selective tropism and efficient gene delivery
2015
A phase III randomized trial of cisplatin plus vindesine versus cisplatin plus vindesine plus mitomycin C versus cisplatin plus vindesine plus ifosfamide for advanced non‐small‐cell lung cancer
1996
Lung Cancer
2008 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics
2007
Lymphangiogenesis: Molecular Mechanisms and Future Promise
2010 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Basis for effective combination cancer chemotherapy with antimetabolites
2000
Soft-Tissue Sarcomas in Adults
2005 Standout
Colorectal cancer
2013 Standout
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
2008
Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens
2001
Lung cancer: current therapies and new targeted treatments
2016 Standout
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
1999
Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study
2000
Evolution of a designed protein assembly encapsulating its own RNA genome
2017 StandoutNatureNobel
Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer
2001
Non-viral vectors for gene-based therapy
2014 Standout
Cellular processing of platinum anticancer drugs
2005 Standout
Cetuximab in advanced non-small cell lung cancer
2006
Engineering targeted viral vectors for gene therapy
2007
Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial
2010
In vivo genome editing using Staphylococcus aureus Cas9
2015 StandoutNature
Distinct Neuronal Coding Schemes in Memory Revealed by Selective Erasure of Fast Synchronous Synaptic Transmission
2012 StandoutNobel
Precise hit: adeno-associated virus in gene targeting
2005
Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere)
2003
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Chemotherapy as treatment of primary and recurrent small cell lung cancer
2001
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non-Small-Cell Lung Cancer
2005
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Adeno-associated virus vector as a platform for gene therapy delivery
2019 Standout
Systematic Meta-Analyses and Field Synopsis of Genetic Association Studies in Colorectal Cancer
2012
Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer
2004
Role of gemcitabine in cancer therapy
2005
Microtubules as a target for anticancer drugs
2004 Standout
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Small-cell lung cancer
2005
The anti-angiogenic basis of metronomic chemotherapy
2004 Standout
Platinum drugs in the treatment of non-small-cell lung cancer
2002
Vascular Targeting: Recent Advances and Therapeutic Perspectives
2006
Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel–cisplatin versus vinorelbine–cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study
2004
Randomized Multicenter Phase II Study of Larotaxel (XRP9881) in Combination with Cisplatin or Gemcitabine as First-Line Chemotherapy in Nonirradiable Stage IIIB or Stage IV Non-small Cell Lung Cancer
2008
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
2009 Standout
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
2008 Standout
A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells
2007
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Current Standards of Care in Small-Cell and Non-Small-Cell Lung Cancer
2001
Anemia of Chronic Disease
2005 Standout
Carboplatin versus cisplatin in solid tumors: An analysis of the literature
1998
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
2013 Standout
The Unexpected Importance of the Primary Structure of the Hydrophobic Part of One-Component Ionizable Amphiphilic Janus Dendrimers in Targeted mRNA Delivery Activity
2022 StandoutNobel
Physiological Implications of Hydrogen Sulfide: A Whiff Exploration That Blossomed
2012 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial
2002
Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Non–Small-Cell Lung Cancer: A Phase III Randomized Trial
2002
Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial
2005 Standout
Phase I clinical trial of weekly combined paclitaxel plus docetaxel in patients with solid tumors
2000
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
2006 Standout
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
1999
Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis
2012
Chemotherapy of advanced non-small cell lung cancer
1999
Cell Cycle Control and Cancer
1994 StandoutScienceNobel
Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer
2007
Virus-mediated gene transfer to induce therapeutic angiogenesis: where do we stand?
2007
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
Silver Nanoparticles: Synthesis, Characterization, Properties, Applications, and Therapeutic Approaches
2016 Standout
Second-Line Chemotherapy in Relapsing or Refractory Non–Small-Cell Lung Cancer: A Review
2000
New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors
1998
Phase II Trial of Irinotecan and Carboplatin for Extensive or Relapsed Small-Cell Lung Cancer
2009
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
2002
Combinatorial Peptide Libraries: Mining for Cell-Binding Peptides
2013
Second-line chemotherapy for non-small cell lung cancer
2002
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Works of E. Papadakis being referenced
First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter phase II study
1998
Vinorelbine-Based Regimens as Salvage Treatment in Patients with Advanced Non-Small Cell Lung Cancer: Two Parallel Multicenter Phase II Trials
2001
Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer
1994
Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: A multicenter phase II study
1998
Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial
2001
Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial
1999
A comparative study of cisplatin and vinblastine versus ifosfamide, cisplatin and vinblastine in non-operable non-small-cell lung cancer
1994
Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial
2001
Front-Line Treatment of Advanced Non–Small-Cell Lung Cancer With Docetaxel and Gemcitabine: A Multicenter Phase II Trial
1999
Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine: a preliminary report on an active regimen.
1997
Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non-small cell lung cancer: A preliminary analysis of a multicenter randomized phase II trial
1999
A multicenter randomized phase III study comparing paclitaxel-cisplatin-etoposide (TEP) versus cisplatin-etoposide (EP) as front-line treatment in patients with small cell lung cancer (SCLC)
2000
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study
2001
P53Arg72 homozygosity and its increased incidence in left-sided sporadic colorectal adenocarcinomas, in a Greek-Caucasian population.
2008
RAS AND P53 EXPRESSION IN NON-SMALL-CELL LUNG-CANCER PATIENTS - P53 OVER-EXPRESSION CORRELATES WITH A POOR PROGNOSIS
1992
A phase II study of docetaxel (D) and gemcitabine (G) as second-line treatment in patients (pts) with advanced non-small cell lung cancer (NSCLC)
1999
Targeted Gene Delivery to Vascular Tissue In Vivo by Tropism-Modified Adeno-Associated Virus Vectors
2004